Designer drugs

NBOME Honors Award Recipients

Retrieved on: 
Thursday, December 20, 2018
25-NB, Designer drugs, National Board of Osteopathic Medical Examiners, Neurochemistry, American Osteopathic Association, Neuropsychology, Neuroscience

John R. Becher, DO, American Osteopathic Association (AOA) president from 2015-2016, and former NBOME board member, presented the award to Mr. Steele, commenting, "He's been indispensable in contracts, negotiations, and all legal issues."

Key Points: 
  • John R. Becher, DO, American Osteopathic Association (AOA) president from 2015-2016, and former NBOME board member, presented the award to Mr. Steele, commenting, "He's been indispensable in contracts, negotiations, and all legal issues."
  • The Santucci Award is named for Thomas F. Santucci, Jr., DO, president and chair of the NBOME Board from 1985 to 1987.
  • This award is given annually to an individual for his or her sustained outstanding contributions to the mission of NBOME.
  • On December 7, 2018, Dr. Walker was honored with the NBOME Clark Award for Patient Advocacy.

New study finds that using fentanyl test strips can lead to safer drug use behaviors

Retrieved on: 
Wednesday, October 3, 2018
Anilides, Piperidines, Synthetic opioids, Designer drugs, Chemistry, Organic chemistry, Neurochemistry, Fentanyl, Drug checking, Benzodioxolefentanyl

In the first-of-its-kind study , RTI examined the use of fentanyl test strips (FTS) among a group of people who inject street opioids in Greensboro, NC.

Key Points: 
  • In the first-of-its-kind study , RTI examined the use of fentanyl test strips (FTS) among a group of people who inject street opioids in Greensboro, NC.
  • The study documents the influence drug checking with FTS can have on drug use behavior.
  • "Our study shows that people who test their drugs with fentanyl test strips and receive a positive test result are willing to perform safer drug use behaviors to prevent overdose," explains Jon Zibbell , a public health researcher at RTI and the study's senior author.
  • Respondents were asked about their most recent fentanyl test strip use and subsequent drug use behaviors.

Cannabics Pharmaceuticals Receives Positive Results in the Development of Cannabinoid-anticancer Drugs

Retrieved on: 
Friday, September 14, 2018
Cannabinoids, Designer drugs

Cannabics is rapidly expanding its database of cancer and cannabinoids and established a library of cannabinoid compounds to explore the biological versatility and entourage effect.

Key Points: 
  • Cannabics is rapidly expanding its database of cancer and cannabinoids and established a library of cannabinoid compounds to explore the biological versatility and entourage effect.
  • The research and development center, in Israel, has leveraged its capabilities and accomplished the implementation of the patented technology.
  • Cannabics is focusing on natural cannabinoids and its R&D open its doors for collaboration in the discovery of new anticancer compounds.
  • Dr. Eyal Ballan, Co-founder and CTO, said: "I am excited to share the positive results and hope for meaningful collaborations with industry leaders in cancer treatment.

Teewinot Life Sciences Corporation Announced Today Grant Of A Canadian Patent With Broad Claims To Biosynthetic Production Of Cannabinoids

Retrieved on: 
Tuesday, September 4, 2018
Cannabinoids, Prodrug, Designer drugs

TAMPA, Fla., Sept. 4, 2018 /PRNewswire/ --Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of Canadian Patent No.

Key Points: 
  • TAMPA, Fla., Sept. 4, 2018 /PRNewswire/ --Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of Canadian Patent No.
  • The '452 patent has broad claims to biosynthetic methods for the production of cannabinoids, cannabinoid prodrugs and cannabinoid analogs.
  • The '452 patent is the first Canadian patent covering biosynthetic production of novel cannabinoids, cannabinoid prodrugs and cannabinoid analogs by means of biocatalysis and synthetic biology.
  • Charlie Brink, Teewinot's Chairman, stated "we are happy to announce the issuance of the '452' patent as it's the first Canadian patent covering biosynthetic production of novel cannabinoids, cannabinoid prodrugs and cannabinoid analogs by means of biocatalysis and synthetic biology.

Teewinot Life Sciences Corporation Announced Today Grant Of A Canadian Patent With Broad Claims To Biosynthetic Production Of Cannabinoids

Retrieved on: 
Tuesday, September 4, 2018
Cannabinoids, Prodrug, Designer drugs

TAMPA, Florida, Sept. 4, 2018 /PRNewswire/ --Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of Canadian Patent No.

Key Points: 
  • TAMPA, Florida, Sept. 4, 2018 /PRNewswire/ --Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of Canadian Patent No.
  • The '452 patent has broad claims to biosynthetic methods for the production of cannabinoids, cannabinoid prodrugs and cannabinoid analogs.
  • The '452 patent is the first Canadian patent covering biosynthetic production of novel cannabinoids, cannabinoid prodrugs and cannabinoid analogs by means of biocatalysis and synthetic biology.
  • Charlie Brink, Teewinot's Chairman, stated "we are happy to announce the issuance of the '452' patent as it's the first Canadian patent covering biosynthetic production of novel cannabinoids, cannabinoid prodrugs and cannabinoid analogs by means of biocatalysis and synthetic biology.

Teewinot Life Sciences Corporation Announced Today Grant of a U.S. Patent with Claims to Cannabinoid Formulations

Retrieved on: 
Tuesday, August 28, 2018
Cannabinoids, Designer drugs, Neuropsychology, Neurochemistry, Neuroscience

TAMPA, Fla., Aug. 28, 2018 /PRNewswire/ --Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of U.S. Patent No.

Key Points: 
  • TAMPA, Fla., Aug. 28, 2018 /PRNewswire/ --Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of U.S. Patent No.
  • 10/052,303 ("the '303 patent").
  • The '303 patent has broad claims to formulations comprising liquid aqueous liposome suspensions constituting one or more cannabinoids or cannabinoid analogs.
  • Teewinot's technology platform enables cost-effective manufacturing and formulation of a large number of naturally-occurring cannabinoids, cannabinoid pro-drugs, and cannabinoid analogs.

Teewinot Life Sciences Corporation Announced Today Grant of a U.S. Patent with Claims to Cannabinoid Formulations

Retrieved on: 
Tuesday, August 28, 2018
Cannabinoids, Designer drugs, Neuropsychology, Neurochemistry, Neuroscience

TAMPA, Florida, Aug. 28, 2018 /PRNewswire/ --Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of U.S. Patent No.

Key Points: 
  • TAMPA, Florida, Aug. 28, 2018 /PRNewswire/ --Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of U.S. Patent No.
  • 10/052,303 ("the '303 patent").
  • The '303 patent has broad claims to formulations comprising liquid aqueous liposome suspensions constituting one or more cannabinoids or cannabinoid analogs.
  • Teewinot's technology platform enables cost-effective manufacturing and formulation of a large number of naturally-occurring cannabinoids, cannabinoid pro-drugs, and cannabinoid analogs.

VUV Analytics Hosting Executive Roundtable on Novel Approaches in Combating the Opioid Crisis and Designer Drug Abuse on the East Coast

Retrieved on: 
Tuesday, July 24, 2018
Drug culture, Designer drugs, VUV, Ultraviolet, Synthetic cannabinoids, Neurochemistry, Neuropsychology, Neuroscience

The event will focus on novel tactics being employed by forensic experts to combat the opioid crisis and the abuse of designer drugs like fentanyl derivatives, synthetic cathinones, and synthetic cannabinoids.

Key Points: 
  • The event will focus on novel tactics being employed by forensic experts to combat the opioid crisis and the abuse of designer drugs like fentanyl derivatives, synthetic cathinones, and synthetic cannabinoids.
  • The half-day event is being held on August 8 at the Courtyard Marriott---Chevy Chase with Ira Lurie, Research Professor, GWU and IUPUI Forensics Department.
  • Invited speakers Dr. Ira Lurie, The George Washington University, and Dr. John Goodpaster, IUPUI, will share recent work in advancing synthetic drug identification.
  • VUV Analytics manufactures universal vacuum ultraviolet (VUV) spectroscopic detectors that provide a new dimension of chemical analysis accuracy.

Sunshine Coast Announces 'Fact Sheet' on Fentanyl and Carfentanyl Crisis in Canada

Retrieved on: 
Tuesday, April 24, 2018
Anilides, Piperidines, Synthetic opioids, Designer drugs, Chemistry, Organic chemistry, Neurochemistry, Fentanyl, Opioid epidemic, Opioid, Benzodioxolefentanyl, Isobutyrylfentanyl

The post explains that fentanyl and carfentanyl belong to the group of drugs known as opioids.

Key Points: 
  • The post explains that fentanyl and carfentanyl belong to the group of drugs known as opioids.
  • They are currently both in the news in relation to the "opioid crisis" that is gripping North America, both Canada and the United States.
  • Fentanyl was created for human use, while carfentanyl was only ever intended for large animal use like elephants.
  • Sunshine Coast Health Centre uses a form of drug rehabilitation based on the research of Viktor Frankl and methodology of Paul T.P.